Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Mostrar otras versiones (1)

Antibodies are becoming a frontline therapy for SARS-CoV-2, but the risk of viral evolutionary escape remains unclear. Here we map how all mutations to SARS-CoV-2’s receptor-binding domain (RBD) affect binding by the antibodies in Regeneron’s REGN-COV2 cocktail and Eli Lilly’s LY-CoV016. These compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Starr, Tyler N., Greaney, Allison J., Addetia, Amin, Hannon, William W., Choudhary, Manish C., Dingens, Adam S., Li, Jonathan Z., Bloom, Jesse D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724661/
https://www.ncbi.nlm.nih.gov/pubmed/33299993
http://dx.doi.org/10.1101/2020.11.30.405472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724661/
https://www.ncbi.nlm.nih.gov/pubmed/33299993
http://dx.doi.org/10.1101/2020.11.30.405472

Ejemplares similares